Colgate Mitigates Currency Crush Via Oral-Care Sales, Price Hikes
This article was originally published in The Rose Sheet
Executive Summary
Price increases in some regions were critical to earnings in Colgate's second quarter, and will continue to be executed at the expense of volume as needed, while oral-care product launches also are helping to offset negative currency effects, the firm reported July 30. With an oral-care business that is “one of the few remaining category killers,” Colgate should consider divesting its home-care and pet-product businesses, an analyst suggests.
You may also be interested in...
North America Anchors Colgate As Currency Headwinds Continue Abroad
Innovation across categories helped make Colgate's North American business its star segment in the second quarter, rising 1.6% to $793m on strong oral care sales, while the firm’s international business remains impacted negatively by currency headwinds.
North America Anchors Colgate As Currency Headwinds Continue Abroad
Innovation across categories helped make Colgate's North American business its star segment in the second quarter, rising 1.6% to $793m on strong oral care sales, while the firm’s international business remains impacted negatively by currency headwinds.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.